GLUE · Monte Rosa Therapeutics, Inc.

$13.51 +0.13 (+0.97%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.14B

85.31M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-07-01	MRT-8102 Phase 1 Clinical Data Update	Event
2026-01-07	Earnings conference call (announced in 8-K)	Earnings call
2025-08-11	AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation	Event
2025-03-20	Monte Rosa Pipeline Update and Clinical Results Presentation (March 20, 2025)	Presentation
2025-03-07	Science – Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition	Event
2024-11-12	San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer	Event
2024-11-09	6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader	Event
2024-08-04	AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	Event
2023-10-17	Monte Rosa Company Call Presentation – October 17 2023	Presentation
2022-10-24	MRT-2359 KOL Webinar, October 24, 2022	Event
2022-01-03	2nd Annual TPD Europe Summit Presentation	Presentation
2021-07-09	European Protein Degradation Congress 2021 Presentation	Presentation
2021-06-10	AACR-NCI-EORTC Late Breaking Presentation	Presentation

Source: https://ir.monterosatx.com/

Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 176 filings 173 filers Visit website Investor relations